| Q55367835 | 18β-Glycyrrhetinic-acid-mediated unfolded protein response induces autophagy and apoptosis in hepatocellular carcinoma. |
| Q28553513 | A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells |
| Q42064611 | A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma |
| Q49960144 | A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma |
| Q60907348 | Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming |
| Q41774349 | Activated Notch signaling augments cell growth in hepatocellular carcinoma via up-regulating the nuclear receptor NR4A2. |
| Q38521011 | Advances in targeted therapies for hepatocellular carcinoma in the genomic era. |
| Q64104618 | Association between quantitative parameters of CEUS and Sall4/Wnt/β-catenin signaling in patients with hepatocellular carcinoma |
| Q33730678 | Association of hepatitis status with surgical outcomes in patients with dual hepatitis B and C related hepatocellular carcinoma |
| Q61788093 | Characterization of Hepatocellular Carcinoma Patients with FGF19 Amplification Assessed by Fluorescence in situ Hybridization: A Large Cohort Study |
| Q37681728 | Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways |
| Q47775953 | Chemotherapy for hepatocellular carcinoma: current status and future perspectives |
| Q92340078 | Circular RNA ABCB10 promotes hepatocellular carcinoma progression by increasing HMG20A expression by sponging miR-670-3p |
| Q40218092 | Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options |
| Q36922232 | Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. |
| Q64100196 | Downregulation of nucleolar and spindle-associated protein 1 expression suppresses liver cancer cell function |
| Q37317562 | Dual oncogenic and tumor suppressor roles of the promyelocytic leukemia gene in hepatocarcinogenesis associated with hepatitis B virus surface antigen |
| Q39366121 | Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma |
| Q55387948 | Exosomes released by hepatocarcinoma cells endow adipocytes with tumor-promoting properties. |
| Q33807832 | Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma. |
| Q28078472 | Gender Differences in Adipocyte Metabolism and Liver Cancer Progression |
| Q28073241 | Genetic alterations in hepatocellular carcinoma: An update |
| Q37164927 | HBV is a risk factor for poor patient prognosis after curative resection of hepatocellular carcinoma: A retrospective case-control study |
| Q38744233 | HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis |
| Q90208536 | HBx/ERα complex-mediated LINC01352 downregulation promotes HBV-related hepatocellular carcinoma via the miR-135b-APC axis |
| Q56907503 | Hepatocellular carcinoma |
| Q39307416 | Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists |
| Q64933154 | Identification of key genes and pathways by bioinformatics analysis with TCGA RNA sequencing data in hepatocellular carcinoma. |
| Q37610670 | Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease |
| Q37580172 | Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. |
| Q31117540 | Integrative Analysis of Microarray Data to Reveal Regulation Patterns in the Pathogenesis of Hepatocellular Carcinoma |
| Q36343345 | Leveraging a Multi-Omics Strategy for Prioritizing Personalized Candidate Mutation-Driver Genes: A Proof-of-Concept Study. |
| Q35903794 | Liver cancer: Approaching a personalized care |
| Q54332985 | Liver cancer: time to evolve trial design after everolimus failure. |
| Q36927013 | Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2. |
| Q38895324 | Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis |
| Q38823802 | MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development |
| Q41636479 | Modeling human liver cancer heterogeneity: virally induced transgenic models and mouse genetic models of chronic liver inflammation |
| Q26745338 | Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances |
| Q26766689 | Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? |
| Q38282800 | New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions |
| Q37457920 | Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing |
| Q38856299 | Nutritional Epigenetics and the Prevention of Hepatocellular Carcinoma with Bioactive Food Constituents |
| Q60922492 | Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion |
| Q37362725 | Potential diagnostic and prognostic marker dimethylglycine dehydrogenase (DMGDH) suppresses hepatocellular carcinoma metastasis in vitro and in vivo |
| Q55345013 | Predicting hepatocellular carcinoma development for cirrhosis patients via methylation detection of heparocarcinogenesis-related genes. |
| Q55035102 | Predicting hepatocellular carcinoma through cross-talk genes identified by risk pathways. |
| Q42343451 | Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future |
| Q30987443 | TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma |
| Q41547180 | Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells |
| Q36356419 | Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib |
| Q92504694 | Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma |
| Q40060996 | Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma |
| Q36048511 | The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling |
| Q38246712 | The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. |
| Q48287375 | The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry. |
| Q47162797 | The utility of biomarkers in hepatocellular carcinoma: review of urine-based 1H-NMR studies - what the clinician needs to know. |
| Q41191439 | Therapeutic strategies for hepatocellular carcinoma: new advances and challenges |
| Q38259343 | Tivantinib: critical review with a focus on hepatocellular carcinoma. |
| Q27853116 | Unique genomic profile of fibrolamellar hepatocellular carcinoma |